➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
Express Scripts
McKesson
McKinsey

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BREXPIPRAZOLE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Brexpiprazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01360632 Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2011-06-01 To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
NCT01360645 Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) Completed Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2011-07-01 To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
NCT01360866 Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) Active, not recruiting Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 2011-10-01 To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
NCT01668797 Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia Completed Quintiles, Inc. Phase 3 2012-10-01 The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brexpiprazole

Condition Name

Condition Name for Brexpiprazole
Intervention Trials
Schizophrenia 14
Major Depressive Disorder 11
Depression 6
Depressive Disorder, Major 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Brexpiprazole
Intervention Trials
Disease 31
Depressive Disorder 23
Depression 23
Depressive Disorder, Major 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Brexpiprazole

Trials by Country

Trials by Country for Brexpiprazole
Location Trials
United States 346
Canada 12
Germany 11
Poland 10
Russian Federation 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Brexpiprazole
Location Trials
California 29
Florida 24
Texas 23
New York 22
Georgia 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Brexpiprazole

Clinical Trial Phase

Clinical Trial Phase for Brexpiprazole
Clinical Trial Phase Trials
Phase 4 3
Phase 3 42
Phase 2/Phase 3 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Brexpiprazole
Clinical Trial Phase Trials
Completed 20
Recruiting 19
Not yet recruiting 17
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Brexpiprazole

Sponsor Name

Sponsor Name for Brexpiprazole
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 35
H. Lundbeck A/S 27
Otsuka Pharmaceutical Co., Ltd. 22
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Brexpiprazole
Sponsor Trials
Industry 93
Other 21
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Dow
Mallinckrodt
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.